InformationJNJ-38877618(OMO-1) JNJ-38877618 (OMO-1) is a potent, highly selective, orally bioavailable Met (c-Met) kinase inhibitor with binding affinity (Kd) of 1.4 nM and enzyme inhibitory activity against wt and M1268T mutant Met (c-Met) (2 and 3 nM IC50).TargetsMet (Cell-free assay); MET (M1268T) (Cell-free assay) 2 nM; 3 nMIn vivoOMO-1 induces complete inhibition of tumor growth in 3 models: the SNU5 MET amp gastric, U87-MG HGF autocrine glioblastoma and Hs746T MET exon 14 skipping mutant gastric cancer. Combination treatments are well tolerated and improve EGFR targeted therapy. Although single agent OMO-1 has no effect on NSCLC HCC827 EGFR, combination with Erlotinib leads to delayed onset of tumor recurrence. Specification: 10mM in DMSO Molecular Formula: C2OH12F2N6 Molecular Weight: 374.35 PubChem CID: 57654476 Isomeric SMILES: C1=CC2=C(C=CC(=C2)C(C3=NN=C4N3N=C(C=C4)C5=CC=NC=C5)(F)F)N=C1
- UPC:
- 12352005
- Condition:
- New
- Availability:
- 8-12 weeks
- Weight:
- 0.85 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- J427023-1ml
- CAS:
- 943540-74-7
- Product Size:
- 1ml
